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ABSTRACT
In Part One of this two-part series, we discussed
skin physiology and anatomy as well as
generalities concerning topical analgesics. This
modality of therapy has lesser side effects and
drug–drug interactions, and patients tolerate
this form of therapy better than many oral
options. Unfortunately, this modality is not
used as often as it could be in chronic pain
states, such as that from neuropathic pain. Part
Two discusses specific therapies, local
anesthetics, and other drugs, as well as how a
clinician might use specific aspects of a patient’s
neuropathic pain presentation to help guide
them in the selection of a topical agent.
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INTRODUCTION
Topical agents do not have a large market share
in the treatment of chronic pain. The total
market for over-the-counter analgesics alone is
estimated at $2.38 billion [1]. In 2007, the
market for topical analgesics (TAs) was only $40
million [2]. These data suggest that these
treatments are underutilized. There are a
number of different potential therapies, other
than diclofenac and lidocaine topical options.
Multiple different medications and mechanisms
are currently being evaluated by the
pharmaceutical industry.
Indeed, some of these mechanisms can be
taken advantage of today, by developing a
working relationship with a pharmacy that
can compound TAs with multiple mechanisms
and different drugs. In line with the repeated
observations that TA use is generally associated
with a more desirable side effect profile than
orally, transdermally, parenterally, or
intrathecally administered analgesics, these
observations should be especially considered
when developing a pain management
treatment regimen for an individual patient.
Currently, only a few options are available in
the market, and clinicians work in concert with
compounding pharmacists to produce various
compounded TAs. This is not a rare occurrence
as an Internet survey of 120 physicians showed
27% of those surveyed used compounded
topical agents as part of their practice [3]. The
research approach of much of the
compounding industry is the (n of 1) trial [4].
This is not unfamiliar to practicing clinicians
who frequently ‘‘try’’ an agent in a given patient
to evaluate efficacy and tolerability.
This review article is based on previously
conducted studies, and does not involve any
new studies of human or animal subjects
performed by any of the authors.
LOCAL ANESTHETIC ANALGESICS:
AN OVERVIEW OF TOPICAL
THERAPIES
Sodium channels are highly expressed in axons
and dendrites as well as centrally [5].
Furthermore, there are multiple channel
subtypes, some of which are involved in the
expression of pain. Although these transient
channels appear very similar, such as voltage-
gated sodium channel (Nav) 1.1–1.7, their
actions are different [6]; Nav1.7, Nav1.8,
Nav1.9 play roles in inflammatory pain [7].
The role for Nav1.3 is controversial and the
channels Nav1.6, and Nav1.1 all warrant more
in-depth investigation [8]. Local analgesic (LA)
agents suppress the activity of peripheral
sodium channels within sensory afferents and
subsequent pain transmission; however, other
mechanisms of action are still under
investigation. There is decreased expression of
messenger ribonucleic acid for specific sodium
channel subtypes following use of LA [9, 10].
Furthermore, LAs preferentially block
hyperexcitable cells [5]. LAs have been used by
topical, intravenous, and subcutaneous routes
in the treatment of chronic pain for years.
Several LAs used as TAs are currently
available including the lidocaine 5% patch
(L5P); the eutectic mixture of LAs, 2.5%
lidocaine/2.5% prilocaine (EMLA); and a
lidocaine 70 mg/tetracaine 70 mg patch (LTP).
Of these three agents, only the L5P is associated
with an analgesic effect without anesthetizing
skin, whereas EMLA or LTP creates both
analgesia and anesthesia. This difference may
be useful in different clinical settings, for
example, venipuncture and circumcision, for
which creating both analgesia and anesthesia
are helpful [10].
The use of specific TAs for the management
of neuropathic pain has been supported by
34 Pain Ther (2015) 4:33–50
evidence from clinical trials and published
reviews [11–13]. Among the currently available
topical options, the L5P has been widely
studied. The outcome of two studies assessed
the tolerability and safety of 24-h use of up to
four L5Ps for extended periods of time. There
were no significant systemic side effects or
dermal reactions, and plasma lidocaine levels
remained low [14, 15]. Safety and tolerability
were similar for either 12- or 24-h application
[10, 14].
LAs have also been studied in conditions not
typically considered responsive, such as low
back pain. For example, a multicenter, open-
label study involved 120 patients with acute
(\6 weeks), subacute (\3 months), short-term
chronic (3–12 months), or long-term chronic
([12 months) low back pain. During the 6-week
study, a majority of patients experienced
moderate or greater pain relief with four L5Ps
applied to the most painful low back areas [16].
A randomized, double-blind, placebo-
controlled trial conducted in Europe evaluated
the analgesic efficacy of the L5P in the
treatment of ‘‘focal’’ neuropathic pain
syndromes, for example, mononeuropathies
and ilioinguinal neuralgia [17]. Adding the
patch to other pharmacotherapeutic regimens
could reduce pain and allodynia as quickly as
within 8 h of application [17]. A smaller open-
label study of 16 patients with various
neuropathic pain conditions, for example,
complex regional pain syndrome (CRPS) or
diabetic peripheral polyneuropathy (DPPN),
demonstrated that the L5P provided pain relief
without significant side effects in 81% of
patients [18]. It is noteworthy that patients
enrolled in this study, prior to the use of the
L5P, had experienced suboptimal outcomes
with other commonly prescribed agents.
Several other noncontrolled studies using the
L5P in patients with DPPN have been
completed. These studies allowed patients to
use as many as four L5Ps for as long as 18 h per
day. Viewing these studies as a group, the
majority of enrolled subjects reported pain
reduction and good tolerability [19, 20]. An
additional 3-week, single-center, open-label
study of the L5P in patients with painful
idiopathic sensory polyneuropathy noted
significant improvements in both pain relief
and quality of life [20]. In a phase IV study of
332 postherpetic neuralgia (PHN) patients using
the L5P, 67% noted decreased pain intensity by
the end of the first week. Further reductions
were noted by the second week in more than
40% of those who had not experienced pain
relief during the first study week. Overall, 70%
of enrolled patients experienced improvement
[21]. In another open-label study, treatment
with the L5P was compared with pregabalin for
PHN. The L5P was at least as effective as
pregabalin in this study. Interestingly, for
patients who had not responded to either
treatment alone, these agents in combination
resulted in greater benefit and tolerability [22].
Changes in PHN pain quality when using the
L5P compared with placebo were evaluated in a
multicenter, randomized, vehicle-controlled
study of 150 patients [23]. Reduced pain
symptoms, assessed using the Neuropathic
Pain Scale, were more likely to occur in the
L5P patients compared with placebo.
Interestingly, neuropathic pain that was deep,
sharp, and burning was previously assumed to
be related to mechanisms of the central, and
not peripheral, nervous system; however, L5P
provided relief for these sensations as well. In
the discussion of the study’s results, it was
proposed that, given the localized primary
peripheral nervous system (PNS) mechanism of
action of the L5P, peripheral mechanisms might
also be important for the development of other
neuropathic pain qualities [23]. Functional
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brain magnetic resonance imaging studies of
patients with PHN treated with the L5P
demonstrated that brain activity appeared to
be modulated in a manner related to the
duration of L5P application, suggesting again
that a peripherally acting agent may have an
impact on central nervous system (CNS) pain
mechanisms [24]. Central neuropathic itch has
been treated successfully with the L5P in a
single case report [25]. Treatment of focal
neuropathic pain with the L5P has also been
shown to be of some benefit in select patients
with cancer [26].
Several studies of the use of EMLA
preparations in treating PHN have shown
mixed results. The results of a randomized,
controlled study of patients with PHN using
EMLA or placebo cream did not result in a
significant difference in treatment outcome
[27]. The results of two uncontrolled studies
were more favorable suggesting that use of the
EMLA could relieve the pain associated with
PHN [28, 29]. Controlled studies have
demonstrated the benefit of EMLA cream in
reducing pain associated with circumcision and
venipuncture as well as in surgery for breast
cancer [10, 30].
CAPSAICIN
Capsaicin, a capsinoid, is a principal pungent
component in the fruits of plants from the
genus Capsicum, which are members of the
nightshade family, Solanaceae [31]. Capsaicin
was first isolated in 1816 in partially purified
crystalline form by Bucholz and in pure
crystalline form in 1876 by Thresh, who
named it capsaicin [32, 33]. Topical capsaicin
appears to act by agonist activity at the TRPV1
receptor on Ad and C fibers, thus causing the
release of substance P and calcitonin gene-
related peptide [34–37]. TRPV1 receptors are
deregulated by inflammation, heat, and
acidification [38]. The results of both human
and animal nerve biopsy studies demonstrate
nerve fiber degeneration beneath the capsaicin
application site. Such degeneration may be one
of the mechanisms of pain relief and has been
termed ‘‘dysfunctionalization’’ [39, 40].
Capsaicin, when applied topically, does not
result in significant systemic accumulation and
the incidence of burning may decrease with
repeated use; however, the frequent occurrence
of this side effect may negatively affect
treatment adherence and consequently the
patient’s ability to benefit from its use [34].
The analgesic effect of capsaicin is dose
dependent and may last for several weeks.
When capsaicin is compounded in a topical
preparation at high concentrations and
administered as a single application, the
analgesic benefit appears to last for several
weeks. Currently, topical liquid preparations of
10% and 20% capsaicin are in phased clinical
trials [41, 42].
There has been interest in using capsaicin in
a number of neuropathic pain disorders such as
DPPN, human immunodeficiency virus
neuropathy (HIVN), and PHN; however, many
of the older studies yielded disappointing
results, perhaps due in part to weakness,
intolerability, efficacy, and adherence of
previously available strengths of capsaicin:
0.025% and 0.075% [43]. For example, 0.025%
capsaicin cream was determined to be no better
than the vehicle (not active) cream in a
randomized, double-blind study of 30 patients
with temporomandibular joint pain [44]. A
review of the published randomized trials
involving low-dose topical capsaicin
concluded that ‘‘although topically applied
capsaicin has moderate to poor efficacy in the
treatment of chronic musculoskeletal or
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neuropathic pain, it may be useful as an adjunct
… for a small number of patients who are
unresponsive to, or intolerant of, other
treatments’’ [45].
However, higher strength capsaicin
preparations have demonstrated better
analgesia. In one study on HIVN, 7.5%
topical capsaicin cream was applied. The
patients experienced notable pain relief, but
required epidural anesthesia to tolerate the
application [46]. In studies leading to
approval of the capsaicin 8% patch (C8P), it
was more efficacious in reducing pain than
an active, lower concentration capsaicin
formulation serving as an active comparator
and was well tolerated. In addition, the C8P
has been studied in other neuropathic pain
states with favorable outcome [47–50].
Efficacy shown from a single 60-min
application in patients with neuropathic
pain produced effective pain relief for up to
12 weeks [51]. Two open-label studies using
the C8P in PHN and HIVN showed a majority
of patients reported pain relief following a
single application, up to 48 weeks [27, 36]. In
a Cochrane review of higher dose capsaicin,
the authors concluded ‘‘High-concentration
topical capsaicin used to treat PHN and HIV
neuropathy generates more participants with
high levels of pain relief than does control
treatment using a much lower concentration
of capsaicin’’ [52].
Substantially fewer studies examining the
use of capsaicin for low back pain or myofascial
pain have been published. A randomized,
double-blind, placebo-controlled study
compared the use of topical capsaicin to
placebo in 154 patients with chronic low back
pain; of these, 60.8% of capsaicin-treated
patients experienced 30% pain relief after
3 weeks of treatment (P\0.02) versus 42.1%
of patients treated with placebo [53].
CYCLOOXYGENASE INHIBITORS
The mechanism of action of a topical
nonsteroidal anti-inflammatory drug (NSAID)
is likely related to anti-inflammatory inhibition
through prostaglandin synthesis via its
adenosine triphosphate-sensitive K? channel
opening property [54, 55]. However, the
extent of anti-inflammatory effect is not
proportional to pain relief, and other
mechanisms of action might be involved [55].
Diclofenac is available in dermal and
transdermal formulations, gels, patches,
creams, and lotions. Since 2007, three topical
NSAIDs have been approved, including
diclofenac sodium gel 1% for treating
osteoarthritis (OA) pain, the diclofenac
epolamine 1.3% topical patch for acute
musculoskeletal pain, and the diclofenac 1.5%
topical solution for OA of the knee [56].
The use of other topical NSAIDs has been
studied most notably outside of the United
States. For example, a topical ketoprofen patch
(100 mg) was found superior to placebo in
reducing pain following 7 days of treatment in
a randomized, placebo-controlled study of 163
patients with ankle sprains [57]. In a separate
study, patients with tendonitis were
randomized in a double-blind, placebo-
controlled study. The NSAID group fared
better than placebo with only minor skin
irritation and was well tolerated [58]. A small
controlled study showed that a topical mixture
of aspirin and diethyl ether was a significantly
more effective analgesic than placebo in
patients with acute herpes zoster and with
PHN [59].
The use of TAs for the treatment of OA has
also been studied and multiple recent reviews
have been published recently [16, 60–62]. A
diclofenac patch preparation demonstrated
safety and efficacy in a randomized, double-
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blind controlled study in patients with chronic
knee OA pain [63]. A randomized controlled
study comparing topical diclofenac solution to
oral diclofenac for knee OA concluded that the
solution produced symptom relief equivalent to
oral diclofenac, but with decreased incidence of
gastrointestinal complaints [64].
Gastrointestinal side effects from oral
diclofenac included abdominal pain, nausea,
dyspepsia, and diarrhea [64]. A recently
published long-term study with the same
topical solution confirmed the safety
parameters of the study [65]. In a pooled
safety analysis of two large studies (one of
which was [64]) comparing oral diclofenac
with a topical diclofenac solution for the
treatment of OA, although the rate of adverse
events (AEs) between the two preparations was
similar, patients treated with the oral diclofenac
experienced more gastrointestinal (39.0% vs
25.4%, P\0.0001) and cardiovascular (3.5% vs
1.5%, P = 0.055) AEs [66]. The oral diclofenac in
the two studies was also associated with
significantly greater increases in liver enzymes
and creatinine, as well as greater decreases in
creatinine clearance and hemoglobin (P\0.001
for all). By contrast, patients receiving the
topical solution had more dry skin at the
application site (24.1% vs 1.9%, P\0.0001)
[66].
Diclofenac solution was compared with oral
diclofenac in a parallel-arm study of individuals
with temporomandibular joint pain. Although
there was no significant difference in analgesic
benefit, there were significantly fewer
gastrointestinal side effects with the topical
solution [67].
Two other trials demonstrated the efficacy of
topical 1.16% diclofenac gel and topical
solution compared with placebo, showing
benefit and safety [68, 69]. In one meta-
analysis, there was evidence to suggest that
topical NSAIDs were more effective than
placebo [70]. However, the authors concluded
that available evidence indicated that topical
NSAIDs were inferior to oral NSAIDs during the
first week of treatment [70]. A separate meta-
analysis examined the use of topical NSAIDs for
chronic musculoskeletal pain and concluded
they are effective and safe [71]. Interestingly,
paraffin baths have been used to alleviate pain
from OA and to improve function. When TAs
were added to the paraffin bath, at least in one
study using essential oils, this increased the
analgesic effect of the bath [72].
A randomized controlled study of a
diclofenac patch in 120 individuals
experiencing acute pain after ‘‘blunt’’ injury
demonstrated that the diclofenac patch was
well tolerated and reduced pain intensity more
than placebo [73]. Two studies, one
noncontrolled and the other a multicenter,
randomized, controlled study, noted that a
diclofenac patch was found to be well
tolerated and effective, with 60% pain relief in
acute sports injuries [74, 75]. In another
controlled study, topical ibuprofen cream was
found to be superior in reducing pain from
acute ankle sprains [76]. In a controlled study of
ketoprofen gel in acute soft tissue pain, the gel
was more effective than placebo in providing
pain relief [77]. A topical formulation of
ibuprofen 5% gel was examined in a 7-day
placebo-controlled study in patients with soft
tissue pain. Patients received either the
ibuprofen 5% gel or placebo gel. A significant
difference (P\0.001) in pain reduction and
improved physical activity was experienced in
the study group [78]. A second similar study
completed by the same investigators
demonstrated similar results [60]. A further
study using topical flurbiprofen for soft tissue
pain reported greater pain reduction than oral
diclofenac and fewer adverse effects [79]. This
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study is one of very few that actually compared
a topical NSAID to an oral agent.
A meta-analysis reviewed the limited data
and concluded that the effects of topically
applied rubefacients containing salicylates
resulted in moderate to poor efficacy. The
authors emphasized that efficacy estimates
were currently unreliable because of poorly
designed clinical trials [80]. A randomized,
controlled study with the topical NSAID
eltenac examined its effect compared with oral
diclofenac and placebo in 290 patients with
knee OA. The TA, compared with placebo,
showed greater safety and efficacy [81]. Each
active treatment, in patients with severe
symptoms, resulted in superior analgesia
compared with placebo, with the incidence of
gastrointestinal side effects lower in the eltenac
gel group compared with that of the oral
diclofenac group [81]. A double-blind placebo-
controlled study in patients with OA of the knee
demonstrated efficacy with a topical diclofenac
patch in reducing pain [82].
In conclusion, the 2007 Cochrane Database
review suggested that topical NSAIDs can
provide good levels of pain relief without
significant systemic adverse effects associated
with oral NSAIDs, for the treatment of acute
musculoskeletal pain [78].
TOPICAL OPIOIDS
Although a large variety of topical transdermal
opioid preparations exist (many for the
treatment of chronic cancer pain), because
these are absorbed systemically (unlike topical
opioid preparations that are not, or not
designed to be, absorbed systemically), they
will not be discussed here. Instead we focus
solely on topical opioid preparations. A
published case series reported the potential
benefit of ‘‘topical’’ morphine in the
management of chronic OA-related pain;
however, the report emphasized that
morphine and/or its metabolites were
identifiable in the urine of treated patients,
thus calling into question how truly ‘‘topical’’
this preparation was, given its systemic effects
[83]. Preclinical studies indicate that opioids
such as morphine, methadone, and
buprenorphine can be analgesics when
administered topically [84–86]. Morphine gel
can be effective in relieving pain of skin ulcers
and calciphylaxis in dialysis patients [87, 88]. A
morphine mouthwash was shown to be safe and
effective in decreasing the severity and duration
of pain in patients with head and neck
carcinomas receiving concomitant
chemoradiotherapy [89]. Loperamide is a
peripherally acting l-opioid agonist. It is
commercially available for the symptomatic
management of diarrhea. It does not
accumulate within the CNS and, when used
topically, may have a LA effect [90]. Topical
opiates have been reported to reduce pain for
two children with epidermolysis bullosa [91].
OTHER DRUG OPTIONS
AND COMBINATIONS
Topical clonidine 0.1% gel significantly
decreases pain in patients with DPPN who had
previously experienced burning pain from
capsaicin applied to the affected skin, an
interesting finding in light of the discussion in
Sect. ‘‘Potential predictors of response to
neuropathic pain treatments’’, below [92]. It
was found to be safe, with application site
reactions only observed in the placebo group
[92]. By contrast, intrathecal clonidine for the
treatment of chronic pain typically results in
hypotension [93]. Topical clonidine can also
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relieve hyperalgesia in patients suffering from
sympathetically maintained pain [94].
Amitriptyline and doxepin are known to
have multiple mechanisms, including local
anesthetic properties, and these drugs may be
analgesic when used topically. Notably,
doxepin is currently available as a cream for
the symptomatic treatment of pruritus [95]. The
results of a novel study comparing the pain-
reducing effect of a topical preparation
containing 3.3% doxepin alone or a topical
preparation containing 3.3% doxepin
combined with 0.075% capsaicin to placebo in
patients with a variety of chronic neuropathic
pain problems indicated that each treatment
provided similar pain-reducing effects and both
were superior to placebo [95]. Although two
clinical trials of amitriptyline, ketamine, and
the combination failed to show efficacy in
patients with neuropathic pain, these have
been used empirically [96, 97]. Observations of
effectiveness of topical amitriptyline alone or in
combination with other drugs, such as
ketamine, have been reported mostly in the
management of painful disorders, for example,
proctodynia [98]. Two open-label trials, the first
involving 28 patients with neuropathic pain
who were treated with the combination
amitriptyline 2%/ketamine 1%, showed pain
reduction and encouraging results [96, 99].
Amitriptyline and ketamine topical
combinations have also been used in patients
suffering from cancer pain, such as in a study
showing that a topical amitriptyline, ketamine,
and lidocaine preparation was safe and effective
in alleviating neuropathic pain caused by
radiation dermatitis [100].
Noncontrolled trials evaluating the use of
topical ketamine, one in patients with PHN and
one in patients with CRPS type 1 have each
concluded that topical ketamine may be
effective; however, serum ketamine levels were
not measured in either study [101]. This would
be instructive to know given the difference in
side effects ketamine has been shown to have
between topical and oral formulations. For
example, topical ketamine at 50 mg/mL was
shown to not elicit any local or systemic side
effects [102], whereas intravenous ketamine for
use in chronic non-cancer pain has been shown
to involve a number of undesirable side effects
that can limit its use, such as tachycardia,
intracranial hypertension, vivid dreams and
hallucinations, and the potential for urinary
tract toxicity [103]. The results of an open-label,
enriched, enrollment study followed by a
randomization to placebo-controlled arms
using either 4% amitriptyline/2% ketamine
cream, 2% amitriptyline/1% ketamine cream,
or placebo for patients with PHN demonstrated
that higher concentrations of study drug
yielded the lowest daily pain intensity
compared with the lower concentration or
placebo [104]. Plasma levels of either drug
were detected in fewer than 10% of study
patients. Topical ketamine has also been
shown to be effective for mucositis pain in a
patient with squamous carcinoma of the tongue
undergoing radiation therapy [105].
Baclofen appears to have peripheral
analgesic properties. Although a GABAergic
agent orally, its hypothesized topical
mechanism of action may be related to its K?
channel opening property [106]. Topical
baclofen has been used empirically in
combination with amitriptyline for vulvodynia
[107], and has been studied as a single agent for
chemotherapy-induced painful neuropathy
[108]. Topical gabapentin has been empirically
used as a single agent or in combination with
amitriptyline and other drugs for neuropathic
pain, with a retrospective study suggesting
benefit of topical gabapentin for vulvodynia
[109].
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Botulinum toxin type A is an oral poison,
which means that the molecule must have an
efficient mechanism of endocytosis to penetrate
and cross not only axon terminals but also
epithelial cells. It is a zinc metalloendoprotease
that cleaves the SNAP-25 protein required for
synaptic vesicle fusion to release transmitters. It
has been approved for the treatment of chronic
migraine. When injected intradermally, a LA
effect for peripheral neuropathic pain was
reported in a small randomized clinical trial
[110].
Dimethyl sulfoxide (DMSO) is a powerful
antioxidant. Antioxidants can prevent or
reduce reactive oxygen species-induced cell
damage and other free radicals known to
promote a neuroinflammatory cascade that, in
some instances, may play a role in the genesis of
chronic pain disorders, such as CRPS. When used
at the concentration of 50% in a cream base,
DSMO appears to be beneficial for CRPS [111–
113]. Palmitoylethanolamide (PEA) is an
endogenous lipid—specifically, a fatty acid
ethanolamide. PEA is an agonist of the
peroxisome proliferator-activated receptor-a
and has been found to possess anti-
inflammatory and anti-nociceptive effects
[114]. In addition, PEA may inhibit the enzyme
that catalyzes the endocannabinoid
anandamide. PEA is available in Europe as an
oral nutraceutical. Some dermatologic creams for
atopic dermatitis contain PEA. It has empirically
been used as a topical treatment for neuropathic
pain [115]. There is one report that suggests that
the topical application of geranium oil may
provide temporary relief from PHN [116].
The analgesic effect of menthol, an
ingredient common to many over-the-counter
analgesic preparations, was hypothesized to be
the result of activation of j-opioid receptors
[117]. Burn pain has been reported to be treated
effectively with a topical loperamide
preparation [118]. Two randomized controlled
studies—one involving postoperative pain
(diclofenac patch) and one involving wound
pain treatment (capsicum plaster topically
applied at acupuncture sites)—have been
published as well [119, 120].
An open-label study using a 0.25% capsaicin
topical agent in a lidocaine vehicle in 25 DPPN
patients and seven PHN patients demonstrated
pain relief in a majority of patients [121]. In a
noncontrolled study of 23 patients with acute
migraine headache, a topically applied 0.1%
capsaicin gel was helpful in reducing mild or
moderate pain [122]. In a randomized, double-
blind study assessing 154 patients with chronic
pain due to lateral epicondylitis, topical glyceryl
trinitrate (0.72 mg/day), compared with
placebo, was found to provide statistically
significant greater pain relief after 8 weeks
[123]. In a study of 52 patients with chronic
pain due to a chronic Achilles tendinopathy,
patients who had been treated with topical
glyceryl trinitrate for 6 months were more likely
3 years after treatment ended to have less pain
and more function than those who had been
treated with placebo [124]. Published reports of
the use of topical phenytoin in the treatment of
pain due to superficial burns or chronic leg
ulcers are noted as well [125, 126].
The use of topical ‘‘essential oxygen oil’’ was
reviewed in a 2010 paper [127]. This essential oil
is a hyperoxygenated, peroxidized, triglycerol-
oxyester-rich oil. Although the published
studies using this approach were open label or
case reports and series, 100% of the patients felt
that their pain was dramatically reduced.
A randomized controlled study of a topical
cream containing glucosamine sulfate,
chondroitin sulfate, and camphor for knee OA
showed a significant pain reduction in the
treatment group compared with the placebo
group [128].
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An interesting study using a homeopathic gel
compared with piroxicam gel in 184 patients with
OA found that ‘‘the homeopathic gel was at least
as effective and as well tolerated as the NSAID gel’’
[129]. A Cochrane review from 2006 evaluating
herbal therapies for low back pain found ‘‘three
low quality trials on Capsicum Frutescens
(Cayenne)’’ used as TAs, finding, ‘‘moderate
evidence that Capsicum Frutescens produced
more favorable results than placebo’’ [130].
Table 1 lists topical non-LAs.
POTENTIAL PREDICTORS
OF RESPONSE TO NEUROPATHIC
PAIN TREATMENTS
Neuropathic pain is accompanied by
somatosensory signs, which include
contributions from peripheral and CNS
structures [131]. As has been discussed in
previous sections of this two-part series,
topical treatments are becoming an alternative
to systemic treatment for peripheral
neuropathic pain syndromes. However, as with
most treatments for chronic pain, the response
cannot be predicted. The variable responses
seen in the previously discussed clinical trials
of L5P and C8P illustrate the difficulty in
predicting individual patient response.
Obviously, if response could be predicted,
patient care would be dramatically improved.
Fortunately, there are data to suggest that
responses using certain topical agents may be
related to certain somatosensory patterns [47,
48, 132–135]. So far, in peripheral neuropathic
pain, no predictors of treatment response have
yet been identified. If certain sensory
characteristics can be identified and associated
with a specific treatment response, this could
lead to improved treatment targeting.
Recent volunteer studies analyzed the
analgesic efficacy of the L5P in two
randomized, double-blind, placebo-controlled,
crossover studies in healthy volunteers using a
capsaicin and a sunburn pain model [136].
Lidocaine and placebo patches were
simultaneously applied to forearms and thighs
at contralateral body sites for three alternating
12-h ‘‘on/off’’ periods. Between the second and
third ‘‘on’’ period, circular spots on both
pretreated thighs were irradiated with
ultraviolet B light to induce inflammatory skin
hyperalgesia. In addition, on the forearms after
the last ‘‘on’’ period, 20 lL of 0.1% capsaicin was
injected intradermally to induce experimental
pain and skin hyperalgesia. The area of pinprick
hyperalgesia was diminished by 53% (P\0.003)
in the capsaicin model and by 84% (P\0.0001)
in the sunburn model; the intensity of
mechanical hyperalgesia to rigid filaments
(8–512 mN) was reduced in both models. The
threshold of cold pain perception was reduced
as well (19.7 C ± 8.0 C vs. 21.8 C ± 6.8 C for
placebo, P\0.05, sunburn). No effect was seen
on capsaicin-induced spontaneous pain, flare
size, blood flow in the sunburn area, or heat
hyperalgesia in either study. These data suggest
that relief of mechanical hyperalgesia is the
predominant effect of the L5P.
Table 1 Topical non-local analgesics
TRPV-1 agonist: capsaicin
Alpha-2 agonists: clonidine
Cyclooxygenase inhibitors acting as analgesics:
aspirin and diclofenac
Single drug or combination of topical medications:
tricyclic antidepressants (amitriptyline, doxepin),
ketamine, baclofen, gabapentin
Botulinum toxin type A
Topical opioids: morphine, loperamide
Antioxidants: dimethyl sulfoxide
Palmitoylethanolamide
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A prospective, observational, open-label
study was undertaken at two pain clinics in
Austria to determine whether any patient
characteristics, including Quantitative Sensory
Testing (QST), can predict response to treatment
with the C8P in patients suffering from
peripheral neuropathic pain [137]. Patients
assessed their pain at baseline and thereafter on
days 1, 7, 28, and 84 posttreatment. QST was
undertaken at the same time points on the
painful area at the region of maximum
peripheral neuropathic pain and on a control
area. In addition, the size of the painful area was
assessed at baseline and days 7, 28, and 84. Of
the 57 patients, a total of 35.2% achieved a 30%
or more reduction in the visual analog scale pain
score at day 7 posttreatment compared with
baseline; these were defined as ‘responders’.
Responders were found to have had a
significantly longer mean duration of
peripheral neuropathic pain than
nonresponders. Analysis of the QST data
showed that the peripheral neuropathic pain
area in responders, but not in nonresponders,
had a significantly lower pressure pain threshold
compared with the control area at baseline.
Furthermore, nonresponders appeared to have
significantly worse allodynia at baseline than
responders, with an approximately three times
greater degree of allodynia in nonresponders
compared with responders across all tests.
Following treatment with the C8P,
responders showed a significant reduction in
allodynia and preexisting mechanical
hypersensitivity and also appeared to show
normalization of pinprick hyperalgesia at some
stimulus levels. Responders to therapy had
significantly greater reductions than
nonresponders in the size of the painful area
at days 28 and 84 following treatment.
However, all patients, including the
nonresponders, had meaningful reductions in
the size of the painful area compared with
baseline values [137]. It can be concluded that
differences can be identified in the sensory
profiles of patients with peripheral
neuropathic pain who respond to the C8P and
those who do not, specifically with regard to
pressure pain threshold and degree of allodynia.
Notably, both responders and nonresponders
experienced meaningful reduction in the size of
the painful area following treatment.
In summary, topical treatments that are
actually available reduce spontaneous
neuropathic pain and predominantly affect
mechanical hyperalgesia, which may serve as a
key marker to predict outcome. Clinical predictors
such as pain intensity and the etiology or type of
pain do not serve as predictors of treatment
response. However, other characteristics that
seem to suggest response, as discussed earlier, are
intriguing and research continues to refine this
diagnostic approach.
CONCLUSION
Of great interest is the recent observation that
although a TA’s primary mechanism of action
may be locally within the PNS, effects can be
detected in the CNS using functional
neuroimaging [138]. Although pain cannot be
experienced without brain activation, a TA may
interrupt pain transmission. Given these results
and the previous discussions, TAs can have a
significant role in patient care. Furthermore,
empirically—although this needs more study—
the use of two or more different compounds in a
given topical gel or cream could target pain
through different mechanisms. This concept of
rational polypharmacy is used in the oral
treatment of neuropathic pain. From the
perspective of this review, this approach could
involve ‘‘rational topical polypharmacy’’, that
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is, an attempt to include two or more TAs to
affect multiple and different pain mechanisms.
In conclusion, although TAs appear to be
underused in clinical practice and have only a
few options that are well studied, they are
effective and may offer clinicians a number of
distinct benefits compared with oral
medications, including fewer side effects and
no drug–drug interactions. Their use in
neuropathic and other chronic pain
syndromes may represent an important
addition to the primary care physician’s and
specialist’s armamentarium for patients of any
pain level.
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